Hepatic fibrosis： It is time to go with hepatic stellate cell-specifictherapeutic targets

作     者：Devaraj Ezhilarasan Etienne Sokal Mustapha Najimi 

作者机构：Biomedical Research Unit and Laboratory Animal CentreSaveetha Dental College and HospitalsSaveetha Institute of Medical and Technical SciencesChennai 600 077Tamil NaduIndia Institut de Recherche Expérimentale et Clinique(IREC)Laboratory of Pediatric Hepatology and Cell TherapyUniversité Catholique de LouvainBrussels 1200Belgium 

出 版 物：《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志（英文版）)

年 卷 期：2018年第17卷第3期

页      面：192-197页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Hepatic stellate cells Apoptosis Autophagy Senescence Extracellular matrix 

摘      要：Hepatic fibrosis is a pathological lesion, characterized by the progressive accumulation of extracellularmatrix （ECM） in the perisinusoidal space and it is a major problem in chronic liver diseases. Phenotypicactivation of hepatic stellate cells （HSC） plays a central role in the progression of hepatic fibrosis. Retardation of proliferation and clearance of activated HSCs from the injured liver is an appropriate therapeutic strategy for the resolution and treatment of hepatic fibrosis. Clearance of activated HSCs from the injuredliver by autophagy inhibitors, proapoptotic agents and senescence inducers with the high affinity towardthe activated HSCs may be the novel therapeutic strategy for the treatment of hepatic fibrosis in the nearfuture.